Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma
Jeremy S. Abramson(Massachusetts General Hospital), Celeste Bello(Moffitt Cancer Center), Robert Redd(Harvard University), Jon Arnason(Beth Israel Deaconess Medical Center), Ronald W. Takvorian(Massachusetts General Hospital), Jeffrey A. Barnes(Harvard University), Robin Joyce(Beth Israel Deaconess Medical Center), Ephraim P. Hochberg(Massachusetts General Hospital), Lubomir Sokol(Moffitt Cancer Center), Ann S. LaCasce(Otsuka (Japan)), David Avigan(Beth Israel Deaconess Medical Center), Donna Neuberg(Otsuka (Japan))
Cited by 51
Related Papers
Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer
|Science|2017|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k